AZN
AstraZeneca plc (NYSE: AZN) faces renewed optimism after Jefferies reiterated its buy rating and 17,500p...
Article Summary
HOLD- AstraZeneca plc (NYSE: AZN) faces renewed optimism after Jefferies reiterated its buy rating and 17,500p price target, citing strong lung data from upcoming presentation at the European Respiratory Society congress as key catalyst.
- The company's experimental lung drug tozorakimab could more than compensate for the collapse of the CARDIO-TTRansform study, which cut $4 billion from longer-term forecasts and reduced growth estimates by 30 basis points.
- The drug targets IL-33, an inflammatory signalling protein released when lung tissue is damaged by smoke or infection, and would be the first medicine of its kind approved for chronic obstructive pulmonary disease, with three trials reporting positive headline results but underlying data not yet published.
- The bank's statistical modelling suggests the drug is likely delivering at least 30% reduction in flare-ups among former smokers, comfortably competitive with Dupixent, with peak sales of more than $5 billion beyond 2030, against consensus of $2.9 billion for 2032.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 9.9% | 25% | 35.0 ptsBelow Screener (9.9%) - Weak growth |
| EPS Growth Next 5Y ? | 12.0% | 25% | 35.0 ptsBelow Screener (12.0%) - Modest outlook |
| Target Price Upside ? | 27.0% | 20% | 75.0 ptsSignificant Upside (27.0%) - Target: $215.41 vs Current: $169.60 |
| Gross Margin % ? | 74.3% | 15% | 100.0 ptsExceptional (74.3%) - Strong pricing power |
| Drawdown from 52-Wk High ? | -20.3% | 15% | 40.0 ptsMild Pullback (-20.3%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About AZN
- AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
- The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI.
- It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines.
- The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases.
- It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia.
- It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates.
- The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999.
- AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.